Table 3 Multivariate Cox regression analyses (Stepwise procedure) (A) in the whole MBC population (n = 244) and (B) in the BM population (n = 86)
Whole MBC population (n = 244) | BM population (n = 86) | |||||
|---|---|---|---|---|---|---|
Parameter | Hazard-ratio | 95% CI | P-value | Hazard-ratio | 95% CI | P-value |
Performance status | ||||||
ECOG 0 | 1 | 1 | ||||
ECOG 1 | 1.90 | 1.17–3.07 | 0.009 | 1.58 | 0.65–3.85 | 0.316 |
ECOG 2 | 2.66 | 1.44–4.90 | 0.002 | 1.63 | 0.54–4.96 | 0.385 |
ECOG 3 | 11.82 | 5.98–23.36 | < 0.001 | 11.16 | 3.50–35.63 | < 0.001 |
Tumor biology | ||||||
HER2+ / HR+ | 1 | 1 | ||||
HER2+ / HR- | 0.97 | 0.56–1.66 | 0.910 | 1.41 | 0.67–2.96 | 0.360 |
HER2- / HR+ | 1.72 | 1.09–2.71 | 0.020 | 2.30 | 1.16–4.56 | 0.017 |
Triple negative | 6.50 | 3.63–11.63 | < 0.001 | 2.54 | 1.00–6.47 | 0.050 |
Patient’s age | ||||||
< 50 | 1 | 1 | ||||
50–70 | 1.67 | 1.08–2.59 | 0.022 | 2.00 | 1.15–3.45 | 0.013 |
≥71 | 1.85 | 0.94–3.64 | 0.077 | 2.06 | 0.90–4.72 | 0.088 |
Number of previous metastatic CT lines | ||||||
0 | 1 | – | ||||
1 or 2 | 1.53 | 0.95–2.47 | 0.080 | |||
> 2 | 2.50 | 1.52–4.12 | < 0.001 | |||
Adjuvant or neoadjuvant CT | – | 1.44 | 0.88–2.38 | 0.148 | ||
Brain metastases | 2.03 | 1.39–2.97 | < 0.001 | – | ||
Neurological deficit associated with BM | – | 2.75 | 1.50–5.03 | < 0.001 | ||
Subcutaneous metastases | 1.85 | 1.26–2.72 | 0.002 | 2.87 | 1.64–5.04 | < 0.001 |
Elevated HER2 ECD (cut-off 15 ng/mL) | 1.88 | 1.21–2.91 | 0.005 | 2.24 | 1.13–4.43 | 0.007 |
Elevated Tau (cut-offs 1.24 and 0.74 pg/mL, respectively) | 1.58 | 1.09–2.31 | 0.017 | 2.43 | 1.16–5.09 | 0.018 |